EA023430B1 - Замещенные производные азоантрацена, фармацевтические композиции и способы их применения - Google Patents

Замещенные производные азоантрацена, фармацевтические композиции и способы их применения Download PDF

Info

Publication number
EA023430B1
EA023430B1 EA201171197A EA201171197A EA023430B1 EA 023430 B1 EA023430 B1 EA 023430B1 EA 201171197 A EA201171197 A EA 201171197A EA 201171197 A EA201171197 A EA 201171197A EA 023430 B1 EA023430 B1 EA 023430B1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenyl
carbonyl
dioxino
amino
propionic acid
Prior art date
Application number
EA201171197A
Other languages
English (en)
Russian (ru)
Other versions
EA201171197A1 (ru
EA201171197A8 (ru
Inventor
Аднан М.М. Мджалли
Кристофер Бем
Дэниел П. Кристен
Дхарма Рао Полисетти
Джеймс Куада
Чидамбаресваран Калпати Сантош
Муралидхар Бондлела
Мустафа Гузель
Равиндра Редди Яррагунта
Деви Редди Гохимуккула
Роберт Карл Эндрюс
Стефен Томас Дэвис
Томас Скотт Йокум
Дженнифер Л.Р. Фримен
Original Assignee
виТиви ТЕРАПЬЮТИКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by виТиви ТЕРАПЬЮТИКС ЭлЭлСи filed Critical виТиви ТЕРАПЬЮТИКС ЭлЭлСи
Publication of EA201171197A1 publication Critical patent/EA201171197A1/ru
Publication of EA201171197A8 publication Critical patent/EA201171197A8/ru
Publication of EA023430B1 publication Critical patent/EA023430B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/201,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Secondary Cells (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201171197A 2009-03-30 2010-03-30 Замещенные производные азоантрацена, фармацевтические композиции и способы их применения EA023430B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (en) 2009-03-30 2010-03-30 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Publications (3)

Publication Number Publication Date
EA201171197A1 EA201171197A1 (ru) 2012-04-30
EA201171197A8 EA201171197A8 (ru) 2014-10-30
EA023430B1 true EA023430B1 (ru) 2016-06-30

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171197A EA023430B1 (ru) 2009-03-30 2010-03-30 Замещенные производные азоантрацена, фармацевтические композиции и способы их применения

Country Status (17)

Country Link
US (3) US8383644B2 (https=)
EP (1) EP2413693B1 (https=)
JP (1) JP5755217B2 (https=)
KR (1) KR101732978B1 (https=)
CN (1) CN102378574B (https=)
AU (1) AU2010232750B2 (https=)
BR (1) BRPI1013579A2 (https=)
CA (1) CA2757084C (https=)
DK (1) DK2413693T3 (https=)
EA (1) EA023430B1 (https=)
ES (1) ES2553645T3 (https=)
IL (1) IL214822A (https=)
MA (1) MA33219B1 (https=)
MX (1) MX2011010347A (https=)
SG (1) SG174205A1 (https=)
TN (1) TN2011000437A1 (https=)
WO (1) WO2010114824A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459937B2 (en) 2020-09-01 2025-11-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
AU2012326361B2 (en) 2011-10-17 2017-08-03 Biotheryx, Inc. Substituted biaryl alkyl amides
AU2014207748B2 (en) 2013-01-17 2018-10-11 Vtv Therapeutics Llc Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
EP3549582B1 (en) 2014-08-29 2024-10-30 The Board of Regents of The University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
MX2020008387A (es) 2018-05-08 2020-12-11 Vtv Therapeutics Llc Usos terapeuticos de agonistas glp1r.
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
WO2020234726A1 (en) * 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
AU2021211437A1 (en) * 2020-01-20 2022-09-15 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
JP2023528726A (ja) 2020-04-01 2023-07-06 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー.,エルティーディー. Glp1rアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202206412A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 製備(s)-2-胺基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯及其鹽酸鹽的方法
TW202206420A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 用於製備glp-1受體促效劑的中間體和方法
CN115667222B (zh) * 2020-05-28 2023-09-29 杭州中美华东制药有限公司 一种制备glp-1受体激动剂的方法
TW202210461A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種(s)—2—胺基—3—(4—(2,3—二甲基吡啶—4—基)苯基)丙酸甲酯二酸鹽的製備方法
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
EP4159737A4 (en) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE
EP4213847A4 (en) * 2020-09-21 2024-12-04 vTv Therapeutics LLC AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE
JP7214053B2 (ja) * 2020-10-08 2023-01-27 イーライ リリー アンド カンパニー 糖尿病治療に有用な6-メトキシ-3,4-ジヒドロ-1h-イソキノリン化合物
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
MX2023006186A (es) 2020-11-27 2023-08-07 Shenzhen Salubris Pharm Co Ltd Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するglp-1受容体作動薬を含有する医薬組成物
CN117500808B (zh) * 2021-06-17 2026-03-06 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
IL309235A (en) 2021-06-24 2024-02-01 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Glp-1 receptor agonist and composition and use thereof
CN117897387A (zh) * 2021-09-03 2024-04-16 杭州中美华东制药有限公司 Glp-1受体激动剂中间体的制备方法
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
CA3233453A1 (en) * 2021-09-28 2023-04-06 Meimei Chen Solid composition of glp-1 receptor agonist
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789675A (en) * 1986-02-11 1988-12-06 Takeda Chemical Industries, Ltd. 1,4-benzoxazine derivatives and pharmaceutical use
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US20060178515A1 (en) * 2003-03-26 2006-08-10 Hamed Aissaoui Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
IL157093A0 (en) 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
JP2005508968A (ja) * 2001-10-19 2005-04-07 トランス テック ファーマ,インコーポレイテッド PTP阻害剤としてのβ−カルボリン誘導体
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
US8466296B2 (en) * 2007-03-26 2013-06-18 Ligand Pharmaceuticals Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
US8718994B2 (en) 2008-04-09 2014-05-06 Transtech Pharma, Llc Ligands for the GLP-1 receptor and methods for discovery thereof
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のglp−1受容体安定化薬および調節薬

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789675A (en) * 1986-02-11 1988-12-06 Takeda Chemical Industries, Ltd. 1,4-benzoxazine derivatives and pharmaceutical use
US20060178515A1 (en) * 2003-03-26 2006-08-10 Hamed Aissaoui Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459937B2 (en) 2020-09-01 2025-11-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
US12473279B2 (en) 2020-09-01 2025-11-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof

Also Published As

Publication number Publication date
EA201171197A1 (ru) 2012-04-30
KR101732978B1 (ko) 2017-05-08
DK2413693T3 (en) 2015-11-16
CA2757084C (en) 2017-08-29
US20130096150A1 (en) 2013-04-18
MX2011010347A (es) 2011-11-29
EP2413693B1 (en) 2015-09-09
EP2413693A1 (en) 2012-02-08
ES2553645T3 (es) 2015-12-10
CA2757084A1 (en) 2010-10-07
SG174205A1 (en) 2011-10-28
AU2010232750A1 (en) 2011-09-08
US9175003B2 (en) 2015-11-03
IL214822A0 (en) 2011-11-30
US8383644B2 (en) 2013-02-26
KR20120006506A (ko) 2012-01-18
EA201171197A8 (ru) 2014-10-30
CN102378574B (zh) 2013-11-20
WO2010114824A8 (en) 2011-10-06
IL214822A (en) 2016-08-31
AU2010232750B2 (en) 2015-10-29
EP2413693A4 (en) 2012-08-22
JP2012522060A (ja) 2012-09-20
US20150148539A1 (en) 2015-05-28
JP5755217B2 (ja) 2015-07-29
HK1164050A1 (en) 2012-09-21
CN102378574A (zh) 2012-03-14
BRPI1013579A2 (pt) 2020-11-03
US20110160198A1 (en) 2011-06-30
US8987295B2 (en) 2015-03-24
MA33219B1 (fr) 2012-04-02
WO2010114824A1 (en) 2010-10-07
TN2011000437A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
EA023430B1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
AU2021390614B2 (en) Glp-1r receptor agonist compound and use thereof
KR101616737B1 (ko) 당뇨병 치료를 위한 옥사디아조안트라센 화합물
JP2022527607A (ja) Glp-1rアゴニスト及びその使用
KR20220112811A (ko) 2-((4-((S)-2-(5-클로로피리딘-2-일)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((S)-옥세탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카르복실산, 1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태
TWI780246B (zh) Trpc 6抑制劑
JP6380402B2 (ja) ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
US12516041B2 (en) Crystal forms of GLP-1R agonists and uses thereof
TW201043619A (en) 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof
RU2712163C2 (ru) Активатор kcnq2-5 каналов
IL223515A (en) Triazaspiroodecanyl compounds and their uses
CN103508931B (zh) 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
WO2022166983A1 (zh) 杂芳基并哌啶类衍生物及其药物组合物和应用
WO2025098465A1 (zh) 稠环衍生物、其制备方法及其在医药上的应用
CN116514802A (zh) 一种二氢吲哚免疫调节抑制剂及其药物组合和用途
CN113527172B (zh) M2乙酰胆碱受体拮抗剂及其用途
HK40115821A (zh) Glp-1受体激动剂及其用途
CN103450214A (zh) 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
WO2008071766A2 (en) Spiro-indene substituted imidazonaphythyridine and pyranoimidazopyridine derivatives as inhibitors of gastric acid secretion

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM